EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer

Jiazhuo He, Lydia Kirsche, Zuzana Nascakova, Francesco Manfredi, Chiara F Magnani, Giovanni Papa, Flora Azizi, Peter Leary, Anne Müller

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-012976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Jiazhuo He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Faculty, University of Zurich, Forschungskredit University of Zürich, Comprehensive Cancer Center Zürich project grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ERBB2/HER2 is overexpressed or mutated in ~15% of gastric cancers due to amplification or mutation of the ERBB2 locus. While the tumor cell-intrinsic consequences of ERBB2 overexpression are well understood, much less is known about its effects on the tumor microenvironment.

Methods

We have developed genetically engineered ectopic and orthotopic syngeneic models of organoid-based gastric cancer that have allowed us to study the tumor microenvironment of ErbB2-overexpressing tumors, using spectral flow cytometry, single cell RNA sequencing, and TCR repertoire sequencing. Interventions such as anti-Erbb2 and anti-PD1 antibody treatments were used as well.

Results

We find that ErbB2 drives the infiltration of CD4 + and CD8 + T-cells, which express granzymes, FasL, and surface markers indicating chronic activation, and in the case of CD8 + T-cells, have undergone clonal expansion. The adoptive transfer of T-cells sorted from ErbB2-overexpressing tumors reduces the growth of ErbB2-expressing, but not control tumors in T-cell-deficient recipients. PD-1-specific checkpoint blockade synergizes with an ErbB2-targeting antibody to reduce the growth of ErbB2-expressing, but not control tumors. Mechanistically, ErbB2 overexpression results in micronuclei formation and the transcriptional activation of numerous interferon-responsive genes in vitro and in vivo; mice lacking the type I interferon receptor show higher engraftment rates and lower T-cell infiltration than wild-type controls.

Conclusions

The combined data indicate that ErbB2, perhaps by driving micronuclei formation, has immunogenic properties that manifest in the form of increased T-cell infiltration and expansion, which can be exploited therapeutically by combining PD1-directed checkpoint blockade with ErbB2-targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsAnimalsMiceHumansOrganoidsTumor MicroenvironmentGenetic EngineeringDisease Models, AnimalCD8-Positive T-LymphocytesCell Line, TumorProgrammed Cell Death 1 ReceptorLymphocytes, Tumor-InfiltratingFemale

Stichwörter der Autor:innen

Gastric CancerT cell Receptor - TCRTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsERBB2 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
  • Department of Medical Oncology and Hematology, University of Zürich and University Hospital Zürich, Zurich, Switzerland.
  • Functional Genomics Center Zürich, University of Zürich and Federal Institute of Technology Zürich, Zürich, Switzerland.
  • Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland mueller@imcr.uzh.ch.

Förderung

  • Medical Faculty, University of Zurich
  • Forschungskredit University of Zürich
  • Comprehensive Cancer Center Zürich project grant
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

He, J., Kirsche, L., Nascakova, Z., Manfredi, F., Magnani, C. F., Papa, G., Azizi, F., Leary, P., & Müller, A. (2026). Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012976

Vancouver

He J, Kirsche L, Nascakova Z, Manfredi F, Magnani CF, Papa G, et al. Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-012976

BibTeX
@article{He2026,
  author = {He, Jiazhuo and Kirsche, Lydia and Nascakova, Zuzana and Manfredi, Francesco and Magnani, Chiara F and Papa, Giovanni and Azizi, Flora and Leary, Peter and Müller, Anne},
  title = {Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-012976}
}
Kostenlos starten →